Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma

Sponsor
University of California, San Francisco
Study ID
NCT00416923
Phase
PHASE1
Status
Completed

Conditions

  • Brain and Central Nervous System Tumors
  • Lymphoma

Eligibility Criteria

Sex
ALL
Age
17 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving rituximab intrathecally may be an effective treatment for recurrent CNS lymphoma. PURPOSE: This phase I trial is studying the side effects and best dose of intrathecal rituximab in treating patients with recurrent CNS lymphoma.

Key Dates

Start date
Aug 31, 2002
Status verified
Feb 2015
Primary completion
Nov 30, 2005
Completion
Apr 30, 2007

Study Design

Enrollment
10 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: intrathecal rituximab
    3 dose levels of intrathecal rituximab, 10mg, 25mg, 50mg

Primary Outcome Measure

Adverse events as a measure of safety of intrathecal administration of Rituximab [ Time Frame: up to 5 years after completion of 5 week study treatment ]

Related Studies